TY UK LIMITED

Company number 05440883 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: TY UK Limited

1. Financial Health Score: B

Grade Justification: TY UK Limited is a profitable, growing business with a strong balance sheet and improving net asset position. However, the significant decline in profitability (PBT down ~60% year-on-year) and reliance on invoice/stock financing prevent a higher grade. The company shows symptoms of margin compression—a condition that, while currently manageable, requires monitoring and corrective action.


2. Key Vital Signs

Metric 2024 2023 Trend Interpretation
Turnover £26.7M £28.1M ↓ 5% Deliberate pricing strategy; volumes increased
Gross Margin 35% 39% ↓ 4pp Margin compression from lower retail pricing
Profit Before Tax £965K £2.4M ↓ 60% Significant profitability decline
Net Assets £7.7M £6.8M ↑ 14% Healthy equity accumulation
Cash £884K £783K ↑ 13% Liquidity improving
Total Liabilities £10.1M £7.2M ↑ 40% Increased borrowing/creditor obligations
Interest Costs £497K £481K → Flat Significant relative to PBT
PBT Margin 3.6% 8.5% ↓ 4.9pp Thin profit buffer
Liabilities-to-Assets 50.8% 50.7% → Stable Moderate leverage

Long-Term Net Assets Trajectory

Year Net Assets
2018 £2.98M
2019 £3.11M
2022 £5.00M
2023 £6.78M
2024 £7.73M

This trajectory shows a patient, compounding growth in shareholder value—comparable to steady bone development in a growing patient.


3. Diagnosis

Overall Financial Condition: Stable but Under Margin Pressure

What the numbers reveal:

The Good News — A Fundamentally Healthy Patient: TY UK Limited has demonstrated remarkable long-term resilience. Net assets have grown from £3.0M in 2018 to £7.7M in 2024—a 159% increase over six years. This is the financial equivalent of a patient who has been building muscle and bone density consistently. The company is profitable, cash reserves are growing, and the auditor has confirmed the going concern basis with no material uncertainties. The business has a clear product strategy (Beanie Bouncer line expansion, new licenses) and active risk management (forward currency contracts, credit checking, invoice/stock financing).

Symptoms Requiring Attention — Margin Compression: The most notable symptom is the sharp decline in profitability. PBT fell from £2.4M to £965K—a 60% drop—despite turnover only falling 5%. This is the financial equivalent of a patient whose blood pressure is rising: not immediately dangerous, but a warning sign. The directors attribute this to a deliberate strategy of keeping retail prices lower to drive volume. While gross profit still covers operating costs, the PBT margin of 3.6% leaves limited room for error.

The Interest Burden — Chronic Condition: Interest costs of £497K now consume over 50% of profit before tax, compared to approximately 20% in 2023. This is like a patient whose medication costs are consuming an increasing share of their budget. The company employs invoice and stock financing, which suggests working capital dependency. While this is common in wholesale distribution, the rising liability position (£10.1M vs £7.2M) warrants monitoring.

Liquidity — Adequate but Not Abundant: Cash of £884K against turnover of £26.7M represents approximately 12 days of revenue. This is functional but not generous. The company is managing cash flow through financing facilities, which is appropriate for a wholesaler but introduces dependency on external funding providers.

No Dividends — Reinvesting in Health: The decision not to pay dividends is prudent given the margin pressure and rising liabilities. This is comparable to a patient choosing to rest and recover rather than pushing through illness.


4. Recommendations

Immediate Actions (0-3 months)

  1. Margin Recovery Plan: The deliberate pricing strategy has driven volume but at significant margin cost. Conduct a price elasticity analysis to identify where modest price increases can be absorbed without volume loss. Even a 1-2% price improvement could add £267K-£534K to gross profit.

  2. Interest Cost Review: With interest costs at £497K, explore refinancing options or alternative funding structures. Even a 0.5% reduction in borrowing rates could save £50K+ annually—meaningful given the current thin margins.

  3. Working Capital Optimization: Total liabilities increased by £2.9M year-on-year. Review debtor days, stock turnover, and creditor terms to ensure the liability growth is proportionate to business activity rather than inefficiency.

Medium-Term Actions (3-12 months)

  1. Product Mix Optimization: The Beanie Bouncer line and expanded licenses are positive strategic moves. Track gross margin by product line and license to identify which products deliver both volume and profitability. Phase out consistently low-margin lines where possible.

  2. Cash Buffer Enhancement: Target building cash reserves to at least £1.5M (approximately 20 days of turnover) to reduce dependency on invoice financing and provide a buffer against economic shocks.

  3. Currency Strategy Validation: The forward contract strategy is sound, but review the proportion of currency exposure hedged versus left floating. The $1.27 average rate achieved was favorable—ensure this strategy is documented and consistently applied.

Long-Term Actions (12+ months)

  1. Profitability Target Setting: Establish a minimum PBT margin target of 5-6% as a "healthy baseline." The current 3.6% is sustainable but leaves insufficient buffer for economic downturns or supply chain disruptions.

  2. Liability Management: Develop a plan to reduce total liabilities as a percentage of total assets from the current ~51% toward 40-45% over the next 2-3 years, strengthening the balance sheet.

  3. Succession and Governance: With multiple family members (name shown to subscribers family) in director roles alongside external director name shown to subscribers, ensure governance structures support objective decision-making, particularly around pricing and investment decisions.


Prognosis

Short-term outlook: Cautiously positive. The directors' commentary indicates 2025 is expected to be a better year, with improving profitability and continued product investment. The Beanie Bouncer line's success (Gold medal at UK Toy of the Year awards) suggests product innovation is working.

Medium-term outlook: Good, contingent on margin recovery. If the pricing strategy successfully builds market share that can later be monetized at improved margins, the current profit dip will be seen as a strategic investment. However, if margins remain at 35% or below, the business will remain vulnerable to interest rate movements and input cost inflation.

Key risk factors: Rising interest costs relative to profit, dependency on external financing for working capital, and the competitive toy market where pricing power is limited.


Names of the people mentioned are shown to subscribers. See subscription

Perspective: Financial Health Diagnostician · Model: glm-5.2 · Generated 2 November 2026